MONTREAL, Sept. 24, 2021 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Firm”) is happy to announce it positioned No. 27 on the 2021 Report on Enterprise rating of Canada’s High Rising Firms.
Canada’s High Rising Firms ranks Canadian corporations on three-year income development. Knight earned its spot with three-year development of two,211%.
“We’re honoured to be acknowledged within the high 10% of The Globe and Mail as one in every of Canada’s High Rising Firms,” stated Samira Sakhia, President and Chief Government Officer of Knight. “The success of the final three years outcomes from our group’s outstanding execution on our technique to construct a number one specialty pharmaceutical firm and to broaden Knight’s operations into Latin America. We’re proud to have efficiently launched a Canadian born enterprise onto the worldwide stage and we’ll proceed to work relentlessly to develop our pan-American ex-US footprint to be able to fulfill our mission of bringing progressive and high-quality branded remedies to enhance the well being of sufferers in Canada and Latin America.”
Launched in 2019, the Canada’s High Rising Firms editorial rating goals to have fun entrepreneurial achievement in Canada by figuring out and amplifying the success of growth-minded, unbiased companies in Canada. It’s a voluntary program; corporations needed to full an in-depth software course of to be able to qualify. In complete, 448 corporations earned a spot on this yr’s rating.
The total checklist of 2021 winners, and accompanying editorial protection, is revealed within the October problem of Report on Enterprise journal—out now—and on-line.
“As we glance towards the long run, Canada’s High Rising Firms provide each inspiration and sensible insights for different companies going through related challenges,” says James Cowan, Editor of Report on Enterprise journal. “The entrepreneurs behind these corporations are sensible, tenacious and unwavering of their dedication to their objectives.”
“Any enterprise chief searching for inspiration ought to look no additional than the 448 companies on this yr’s Report on Enterprise rating of Canada’s High Rising Firms,” says Phillip Crawley, Writer and CEO of The Globe and Mail. “Their development helps to make Canada a greater place, and we’re proud to convey their tales to our readers.”
About The Globe and Mail
The Globe and Mail is Canada’s foremost information media firm, main the nationwide dialogue and inflicting coverage change via courageous and unbiased journalism since 1844. With award-winning protection of enterprise, politics and nationwide affairs, The Globe and Mail newspaper reaches 6.4 million readers each week in print or digital codecs, and Report on Enterprise journal reaches 2 million readers in print and digital each problem. The Globe and Mail’s funding in progressive information science signifies that because the world continues to alter, so does The Globe. The Globe and Mail is owned by Woodbridge, the funding arm of the Thomson household.
About Knight Therapeutics Inc.
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical firm centered on buying or in-licensing and commercializing progressive pharmaceutical merchandise for Canada and Latin America. Knight owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical firm. Knight Therapeutics Inc.’s shares commerce on TSX beneath the image GUD. For extra details about Knight Therapeutics Inc., please go to the corporate’s website online at www.gud-knight.com or www.sedar.com.
This doc incorporates forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, essentially contain dangers and uncertainties that would trigger precise outcomes to vary materially from these contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are primarily based to be cheap on the time they have been ready however cautions the reader that these assumptions relating to future occasions, a lot of that are past the management of Knight Therapeutics Inc. and its subsidiaries, could in the end show to be incorrect. Elements and dangers, which may trigger precise outcomes to vary materially from present expectations are mentioned in Knight Therapeutics Inc.’s Annual Report and in Knight Therapeutics Inc.’s Annual Data Kind for the yr ended December 31, 2020 as filed on www.sedar.com. Knight Therapeutics Inc. disclaims any intention or obligation to replace or revise any forward-looking statements whether or not because of new data or future occasions, besides as required by regulation.